Synta Pharmaceuticals announced that ganetespib has demonstrated clinical activity in heavily pre-treated patients with HER2-positive and triple negative metastatic breast cancer. In a Phase 2 trial, two of the thirteen patients with the HER2 gene amplification experienced a partial response, and an additional six achieved stable disease. In one of three evaluable patients with triple negative breast cancer, significant tumor shrinkage occurred following three doses of ganetespib.
Ganetespib is a potent, synthetic, small-molecule inhibitor of heat shock protein 90 (Hsp90). Hsp90 is a molecular chaperone required for the proper folding and activation of many cancer-promoting proteins, and is recognized as a key facilitator of cancer-cell growth and survival.
For more information, call (781) 274-8200 or visit www.syntapharma.com.